Loading...
•
Mar 31, 2024
Atea Q1 2024 Earnings Report
Atea Pharmaceuticals reported financial results for the first quarter of 2024 and provided a business update.
Key Takeaways
Atea Pharmaceuticals reported its financial results for Q1 2024, highlighting the completion of enrollment in the Phase 3 SUNRISE-3 trial for COVID-19 treatment and advancements in the Phase 2 HCV study. The company's cash, cash equivalents, and marketable securities totaled $541.5 million.
Completed enrollment in the global Phase 3 SUNRISE-3 trial for COVID-19 treatment ahead of schedule, with results expected in the second half of 2024.
Advanced enrollment in the global Phase 2 study evaluating the combination of bemnifosbuvir and ruzasvir in treatment-naïve, HCV-infected patients.
Presented preclinical and new Phase 2 efficacy data at the European Association for the Study of the Liver (EASL) Congress 2024.
Reported cash, cash equivalents, and marketable securities of $541.5 million as of March 31, 2024.
Forward Guidance
Atea Pharmaceuticals anticipates reporting results from the SUNRISE-3 trial in the second half of 2024 and topline results from all patients enrolled in the Phase 2 HCV study in the second half of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...